IPSEN (OTCMKTS:IPSEY) Shares Gap Down – Here’s Why

IPSEN (OTCMKTS:IPSEY) gapped down before the market opened on Friday . The stock had previously closed at $47.11, but opened at $44.81. IPSEN shares last traded at $44.81, with a volume of 170 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Zacks Research raised IPSEN to a “hold” rating in a research report on Friday, May 29th. Finally, HC Wainwright reiterated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold”.

IPSEN Trading Down 4.9%

The firm has a 50-day simple moving average of $46.28 and a 200 day simple moving average of $45.15.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).